Effects of GLP1 receptor analogues in obesity with neurodevelopmental disorder: case report of a patient with holoprosencephaly.
Manon Le GuiniecAnne Laure BorelPublished in: European journal of clinical nutrition (2024)
Holoprosencephaly is an anomaly in the division of the prosencephalon into cerebral hemispheres during the second month of gestation. Patients can present with early-onset obesity favoured by the cognitive impairment. We present a case of a 24 year-old woman with holoprosencephaly and class III obesity who was treated by 2.4 mg/week SEMAGLUTIDE. Her body weight decreased from 115.3 to 94.3 kg after one-year (18% of total body weight loss). In addition, she presented a marked reduction in self- and hetero-aggressive behaviour when exposed to the sight of food. The treatment was well tolerated, with the exception of a few vomiting when eating palatable food too quickly. GLP1-RAs may be interesting for obesity treatment in the context of neurodevelopmental disorders. They appear to reduce compulsive eating and aggressive behaviour, particularly in relation to exposure to food, and lead to weight loss similar to that seen in people without neurodevelopmental disorders.
Keyphrases
- weight loss
- bariatric surgery
- early onset
- roux en y gastric bypass
- case report
- gastric bypass
- body weight
- weight gain
- cognitive impairment
- insulin resistance
- metabolic syndrome
- type diabetes
- glycemic control
- end stage renal disease
- high fat diet induced
- late onset
- ejection fraction
- obese patients
- preterm infants
- chronic kidney disease
- clinical trial
- prognostic factors
- randomized controlled trial
- physical activity
- brain injury
- climate change
- peritoneal dialysis
- adipose tissue
- skeletal muscle
- body mass index
- obsessive compulsive disorder
- cerebral ischemia
- cerebral blood flow
- molecular dynamics simulations